tirzepatide surpass trials Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT SURPASS-CVOT trial: For patients with
Description
Norm-based scores greater than and less than 50 are greater than and less than the average, respectively, found in the 2009 US general population
The booklet summarises these patient-relevant benefits explicitly: manages blood sugar to reach HbA1c goals, helps with weight loss, and can help prevent heart disease
Liver dysfunction can lead to metabolite buildup either from overproduction or impaired elimination
Tirzepatide activates both GLP-1 and GIP receptors, and GIP in particular plays a role in lipid metabolism by influencing how fat is stored and processed after meals
